SynthesisOncotarget2016

The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.

Tengfei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.